Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2011-07-12
2011-07-12
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S277100
Reexamination Certificate
active
07976846
ABSTRACT:
Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. The pharmaceutical compositions of the invention can be administered to a subject, thereby providing methods for inhibitingM. tuberculosis-infection, for inhibiting tumor growth, for inhibiting the development of a cancer, and for the treatment or prevention of infectious disease. The invention further provides a method for producing T cells directed against a tumor cell or aM. tuberculosis-infected cell, wherein a T cell is contacted with an APC that is modified to present an hsp110 or grp170 polypeptide and an immunogenic polypeptide associated with a tumor or with theM. tuberculosis-infected cell. Included in the invention are T cells produced by this method and a pharmaceutical composition comprising such T cells. The T cells can be contacted with aM. tuberculosis-infected cell in a method for killing aM. tuberculosis-infected cell, or with a tumor cell in a method for killing a tumor cell.
REFERENCES:
patent: 5066579 (1991-11-01), Reyes
patent: 5550214 (1996-08-01), Eberlein et al.
patent: 5726023 (1998-03-01), Cheever et al.
patent: 5747332 (1998-05-01), Wallen et al.
patent: 5830464 (1998-11-01), Srivastava
patent: 5888795 (1999-03-01), Hamilton
patent: 5891432 (1999-04-01), Hoo
patent: 5961979 (1999-10-01), Srivastava
patent: 5981706 (1999-11-01), Wallen et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6017540 (2000-01-01), Srivastava et al.
patent: 6066716 (2000-05-01), Wallen et al.
patent: 6156302 (2000-12-01), Srivastava
patent: 6162436 (2000-12-01), Srivastava
patent: 6187312 (2001-02-01), Srivastava
patent: 6268213 (2001-07-01), Samulski et al.
patent: 6322790 (2001-11-01), Srivastava
patent: 6331299 (2001-12-01), Rothman et al.
patent: 6403095 (2002-06-01), Srivastava et al.
patent: 7157089 (2007-01-01), Mizzen et al.
patent: WO 94/29459 (1994-12-01), None
patent: WO 95/24923 (1995-09-01), None
patent: WO 96/10411 (1996-04-01), None
patent: WO 97/06821 (1997-02-01), None
patent: WO 97/10000 (1997-03-01), None
patent: WO 97/10001 (1997-03-01), None
patent: WO 97/10002 (1997-03-01), None
patent: WO 97/26910 (1997-07-01), None
patent: WO 98/23735 (1998-04-01), None
patent: WO 98/34641 (1998-08-01), None
patent: WO 98/35705 (1998-08-01), None
patent: WO 99/07860 (1999-02-01), None
patent: WO 00/44899 (2000-08-01), None
Donnelly et al (Journal of Immunology, Jul. 15, 2005 175(2):633-639).
Vanniasinkam et al (Journal of clinical virology, Aug. 2006, 36(4):292-297).
Welch et al (Journal of Cell biology, 1985, vol. 101, pp. 1198-1211).
Subjeck et al (Radiation Research, .1992, vol. 2, pp. 986-991).
Spee et al (Biochemistry, 1999, vol. 38, pp. 10559-10566).
Hughes et al (Cancer, 1970, vol. 26, pp. 269-278).
Wang et al, (International Journal of Cancer, 2003, vol. 105, pp. 226-231).
Kutomi et al (Journal of Immunology, 2009, vol. 183, pp. 5861-5869).
Young et al (Ann Rev Immunology, 1990, vol. 8, pp. 4012-4200).
Suto et al (Science, 1995, vol. 269, pp. 1585-1587).
A.L. Rakhmilcvich et al., “Effective Particle-mediated Vaccination Against Mouse Melanoma by Coadministration of Plasmid DNA Encoding Gp100 and Granulocyte-Macrophage Colony-Stimulating Factor,” Cancer Research, 2001, 7: 952-961.
C.I. Bargmann et al., “The neu oncogene encodes an epidermal growth factor receptor-related protein,” 1986, Nature. 319(16):226-230.
C.I. Bargmann et al., “Multiple Independent Activations of the neu Oncogene by a Point Mutation Altering the Transmembrane Domain of p. 185.” 1986. Cell, 45:649-657.
N.E. Blachere et al., “Heat Shock Protein-Based Cancer Vaccines and Related Thoughts on Immunogenicity of Human Tumors,” Cancer Biology, 1995, vol. 6: 349-355.
N.E. Blachere et al., “Heat Shock Protein Vaccines Against Cancer,” Jnl. of Immunology, 1993, 14(4): 352-356.
W.R. Boorstein et al., “Molecular Evolution of the HSP70 Multigene Family,” 1994,J Mol Evol, 38:1-17.
C-II Chen et aL, “Enhancement of DNA Vaccine Potency by Linkage of Antigen Gene to an HSP70 Gene,” Cancer Research, 2000, vol. 60: 1035-1042.
X. Chen et al., “The 170 kCa glucose regulated stress protein is a large HSP70-HSP110-like protein of the endoplasmic reticulum,” XP-002060249,1996. FEBS Letters, 380:68-72.
R.N. Coler, “Molecular Cloning and Immunologic Reactivity of a Novel Low Molecular Mass Antigen ofMycobacterium tuberculosis1,” 1998, Immun, 161(5):2356-2364.
D.C. Dillon et al., “Molecular Characterization and Human T-Cell Responses to a Member of a NovelMycobacterium tuberculosis,” XP-002143391. 1994. Infection and Immunity. pp. 2941-2950.
M.L. Disis et al., “Generation of Immunity to the HER-2
euOncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine,” Clinical Cancer Research, 1999, vol. 5: 1289-1297.
T. Hatayama et aL, “Association of HSP105 with HSC70 in High Molecular Mass Complexes in Mouse FM3A Cells,” 1998, Biochem and Biophys Res Comm, 248:395-401.
S. Janetzki et al., “Immunization of Cancer Patients with Autologous Cancer-Derived Heat Shock Protein gp96 Preparations: A Pilot Study,” International Jnl. of Cancer, 2000, vol. 88: 232-238.
S. Jindal, “Heat shock proteins applications in health and disease,”1996, TB Tech, vol. 14, p. 5.
Z. Li, “Priming of T Cells by Heat Shock Protein-Peptide Complexes as the Basis of Tumor Vaccines,” Seminars in Immunology, 1997, vol. 9: 315-322.
M.H. Manjili et al., “Development of a Recombinant HSP110-HER-2
euVaccine Using the Chaperoning Properties of HSP110.” Cancer Research. 2002, vol. 62: 1737-1742.
M.H. Manjihi et al., “Immunotherapy of Cancer Using Heat Shock Proteins,” Frontiers in Bioscience, 2002, vol. 7: d43-52.
A. Menoret et al., “Heat-Shock Protein-Based Anticancer Immunotherapy: An Idea Whose Time Has Come,” Seminars in Oncology. 1998, 25(6): 654-660.
Y. Moroi et al., “Induction of Cellular Immunity by Immunization with Novel Hybrid Peptides. Complexed to Heat Shock Protein 70.” PNAS, 2000, 97(7): 3485-3490.
H. Oh et al., “The Chaperoning Activity of hsp110,” 1999,J of Biol Chem, 274(22):15712-15718.
D. Przepiorka et al., “Heat Shock Protein-Peptide Complexes as Immunotherapy for Human Cancer,” Molecular Medicine Today, 1998, 4(11): 478-484.
T. Shyy et al., “Effect of Growth Stare and Heat Shock on Nucleolar Localization of the 110,000-Da Heat Shock Protein in Mouse Embryo Fibroblasts1,” 1986. Cancer Research, 46:4738-4745.
P.K. Srivastava, “Purification of Heat Shock Prorein-Pcptide Complexes for Use in Vaccination Against Cancers and Intracellular Pathogens,” Methods: A Companion to Methods in Enzymology, 1997, vol. 12: 165-171.
K. Suzue et al., “Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway,” 1997, Proc Nad Acad Sci USA, 94:13146-13151.
Y. Tamura et al., “Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations,” Science, 1997, vol. 278: 117-120.
H. Uduno et al., “Generation of Cytotoxic T Lymphocytes by MHC Class I Ligands Fused to Heat Shock Cognate Protein 70,” International Immunology, 2001,13(10): 1233-1242.
D.K. Vanaja et al., “Tumor Prevention and Antitumor Immunity with Heat Shock Protein 70 Induced by 15-Deoxy-Δ12,14-prostaglandin Ja in Transgenic Adenocarcinoma of Mouse Prostate Cells,” Cancer Research, 2000, vol. 60: 4714-4718.
X-Y. Wang et al., “Characterization of Heat Shock Protein 110 and Glucose-Regulated Protein 170 as Cancer Vaccines
Henderson Robert A.
Kazim Latif
Repasky Elizabeth A.
Subjeck John R.
Wang Xiang-Yang
Canady Karen S.
Canady & Lortz LLP
Canella Karen A
Health Research , Inc.
LandOfFree
Stress protein compositions and methods for prevention and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stress protein compositions and methods for prevention and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stress protein compositions and methods for prevention and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2641726